Studies on the effect of 9-(R, S)-(2,3-dihydroxypropyl)adenine on tick-borne encephalitis virus.
Peroral treatment with 9-(R, S)-(2,3-dihydroxypropyl) adenine did not protect mice infected with tick-borne encephalitis (TBE) viruses (strains Hypr and Ir13) when the drug was administered at the time or infection and/or up to day 2 after infection. The analogue inhibited the haemagglutination activity of the Skalica strain in vitro.